Oxygenta Pharmaceutical (524636) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
20 Nov, 2025Executive summary
Audited financial results for Q4 and full year ended March 31, 2025, were approved by the board and reviewed by the audit committee.
The company shifted its corporate office within Hyderabad effective May 30, 2025.
Financial highlights
Q4 FY25 revenue from operations was ₹4,946.66 lakhs, up from ₹1,055.24 lakhs in Q4 FY24.
Total income for FY25 was ₹11,060.77 lakhs, compared to ₹3,968.45 lakhs in FY24.
Net loss for FY25 stood at ₹1,029.83 lakhs, versus a loss of ₹347.93 lakhs in FY24.
Q4 FY25 net loss was ₹215.29 lakhs, compared to a net profit of ₹801.58 lakhs in Q4 FY24.
Basic and diluted EPS for FY25 was (₹2.86), compared to (₹1.04) in FY24.
Outlook and guidance
The company is prioritizing compliance and transparency, focusing on accurate MSME creditor identification and bill-to-bill adjustment processes.
Latest events from Oxygenta Pharmaceutical
- Revenue up, losses down, and government credit secured in Q1 FY 2026-27.524636
Q1 26/27 - FY26 revenue rose but net loss deepened; board changes and compliance focus highlighted.524636Q4 25/26
- Revenue rose but net losses widened in Q3 FY26; compliance and creditor processes are ongoing.524636Q3 25/26
- Revenue rose modestly, but losses widened; new CFO appointed and compliance efforts ongoing.524636Q2 25/26
- Q1 FY26 saw higher revenue but a deeper net loss, with new auditor and compliance appointments.524636Q1 25/26
- Q2 FY25 revenue grew and net loss narrowed, with key statutory and compliance actions taken.524636Q2 24/25
- Q1 FY25 revenue up, net loss narrows, equity raised via share allotment; compliance issues persist.524636Q1 24/25
- Q3 FY25 revenue surged, but losses deepened and compliance issues remain under review.524636Q3 24/25